Neurocrine Biosciences (NBIX) Accounts Payables (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Accounts Payables for 17 consecutive years, with $808.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables rose 65.13% year-over-year to $808.3 million; the trailing twelve-month figure through Jun 2026 stood at $808.3 million (up 65.13% YoY), and the FY2025 full-year result was $674.3 million, up 46.08% from the prior year.
• Accounts Payables rose to $808.3 million in Q2 2026 per NBIX's latest filing, from $773.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $808.3 million in Q2 2026 and bottomed at $235.9 million in Q1 2022.
• Historically, Accounts Payables has averaged $460.0 million across 5 years, with a median of $433.0 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables soared 68.91% in 2023, then slipped 21.93% in 2024.
• Over 5 years, Accounts Payables stood at $347.6 million in 2022, then rose by 29.11% to $448.8 million in 2023, then increased by 2.85% to $461.6 million in 2024, then jumped by 46.08% to $674.3 million in 2025, then climbed by 19.87% to $808.3 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $808.3 million, $773.0 million, and $674.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.